GT Biopharma, Inc. amended its bylaws-to-reduce the quorum requirement for stockholder-to-meetings. The Board of Directors approved an amendment effective June 8, 2026, which reduced the holders of not less than one-third (1/3) of outstanding shares to constitute a quorum. This change was implemented to address difficulty in obtaining a majority quorum due to brokerage firms opting to forgo discretionary voting of shares held in street name. GT Biopharma, Inc. is a biotechnology company focused on research and development of biological products.